The commercial agreement replaces the Letter of Intent (LOI) announced on 17 June 2025 and means that the parties have now fully agreed on all commercial terms of the collaboration. Under the agreement, Glenmark will be responsible for the commercialisation of the product in each respective market. The agreement covers a total population of over 160 million people and represents an important step in AcuCort's ongoing international expansion.

"Having a commercial agreement in place with Glenmark is a very significant milestone for AcuCort. Germany is one of Europe's largest and most important pharmaceutical markets, and the agreement confirms both the commercial potential of the product and our long-term expansion efforts," said Jonas Jönmark, CEO of AcuCort AB.

"The product strengthens our Europe portfolio and aligns well with our focus on differentiated therapies. This partnership reflects our ability to execute across multiple European markets. By leveraging our established commercial infrastructure and regional expertise, we aim to ensure timely and reliable access to this therapy for patients while creating long-term value for healthcare systems," said Christoph Stoller, President & Business Head - Europe & Emerging Markets, Glenmark Pharmaceuticals.

Glenmark is the Market Authorisation Holder (MAH) for the product and is responsible for the regulatory submission of marketing authorisation applications in the relevant markets. Glenmark expects the application to be submitted in the second half of 2026.

The product was launched in Sweden, Norway and Finland in the autumn of 2024 and in Denmark in summer 2025. During the spring of 2025, repeat orders were placed for the Nordic region, followed by a further order in December 2025. The final agreement with Glenmark Pharmaceuticals builds on AcuCort's strategy of leveraging the Nordic region as a springboard for broader global presence.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, specialty, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

About AcuCort AB (publ)

AcuCort has developed and is commercialising Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a well-known substance in a new, innovative, patented, and novel administration form primarily for the treatment of severe and acute allergic reactions, asthma, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is available on the markets in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.
 

About Zeqmelit®

With the development of Zeqmelit®, AcuCort has combined the benefits of the well-established active substance dexamethasone with the company's patented, fast-dissolving oral film to enable rapid availability and relief in acute situations, such as acute allergic reactions and croup in young children. The active substance, dexamethasone, belongs to the class of glucocorticoids - a well-known and established group of medicines with extensive clinical use since the 1960s.

For more information, please contact: